Skip to main content

Table 2 Laboratory parameters of total cohort and subcohorts with and without thromboembolic events

From: Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis

 

Cohort (N = 40)

Thromboembolic event

  

Yes (N = 23)

No (N = 17)

 

Median

[IQR]

Median

[IQR]

Median

[IQR]

p value

Laboratory variables (normal values)

 Haemoglobin (12·5–17·2 g/dL)

10.1

[8.5–11.2]

9.70

[8.3–10.8]

10.4

[9.3–11.9]

ns

 White blood cells (3·5–10·5/nl)

10.13

[7.5–13.7]

10.63

[7.4–16]

9.58

[6.6–12.1]

ns

 Platelet count (150–370/nl)

193.5

[131.3–316.3]

181

[116–306]

209

[178–325.5]

ns

 Prothrombin time (70–130%)

74.5

[62.8–86]

79

[61–83]

71

[63.5–87.5]

ns

 INR (0·9–1·25)

1.2

[1.1–1.4]

1.18

[1.1–1.4]

1.26

[1.1–1.4]

ns

 PTT (26–40 s)

45.65

[39.4–56.1]

51.10

[40.8–57.4]

41.1

[38.7–54.2]

ns

 Fibrinogen (1·6–4 g/l)

6.67

[4.7–7.7]

6.72

[5.0–7.8]

6.1

[4.6–7.9]

ns

 D-dimers (< 0·5 mg/l)

3.95

[2.6–5.9]

4.84

[3.5–7.2]

3.06

[2.3–3.9]

0.003

 max. D-dimers (< 0·5 mg/l)

8.25

[3.6–16.2]

11.57

[8.2–18.4]

3.98

[2.6–6.4]

< 0.001

 Procalcitonin (0·5 µg/l)

0.57

[0.2–2.5]

0.81

[0.4–4.7]

0.24

[0.2–1.3]

ns

 CRP (< 0·5 mg/l)

123.8

[84.3–216.5]

130

[86–273.7]

111

[79.3–185]

ns

 max. CRP (< 0·5 mg/l)

312.9

[208.3–343.9]

341.4

[261.1–370.7]

261.05

[175.3–312.9]

0.002

 IL-6 (< 7 ng/l)

103

[35·6–230]

88

[27.7–340]

153

[53.7–206.5]

ns

 max. IL-6 (< 7 ng/l)

558.6

[178.8–1792.3]

550

[174–2475]

567.2

[186.5–1196.5]

ns

 Ferritin (30–400 µg/l)

1636

[1067.8–4028.5]

1663

[1218.5–4655]

1567

[720–3662]

ns

 max. Ferritin (30–400 µg/l)

2523.2

[1536.7–6635.1]

2781.5

[1854.7–7996.2]

2028.4

[922.9–4893.4]

ns

 tPA (2–8 µg/l)

1

[0.9–5.5]

1

[0.9–3.6]

2

[0.9–9.9]

ns

 PAI-1 (7–43 ng/ml)

36

[17–70]

31

[12–61]

42.50

[25.3–87]

ns

 tPA/PAI-1

0.053

[0.02–0.18]

0.05

[0.02–0.14]

11

[0.03–0.24]

ns

 Antithrombin III (80–120%)

79

[58.5–96.5]

75.5

[56.8–84]

94

[66.5–110]

ns

 Factor VIII (50–150%)

258

[190.5–319.5]

260

[219.5–355]

222

[149.5–289.5]

ns

 Plasminogen (80–120%)

88

[72.8–114]

82

[72.8–109.8]

101

[70.8–129.8]

ns

ROTEM variables

 FIBTEM CT (s)

88.5

[78–97.8]

89

[78–102]

88

[75.5–96]

ns

 FIBTEM CFT (s)

68

[51–104]

64.5

[54–95.8]

71

[47–165]

ns

 FIBTEM MCF (mm)

34.5

[27.3–39.5]

35

[27–38]

34

[27–40]

ns

 EXTEM CT (s)

86

[69.5–99.8]

84

[69–96]

86

[70.5–107.5]

ns

 EXTEM CFT (s)

46.5

[40–60.5]

47

[40–61]

45

[40.5–56.5]

ns

 EXTEM MCF (mm)

75

[70.3–78]

75

[69–78]

76

[72.5–78.5]

ns

 INTEM CT (s)

208

[181.3–227.5]

215

[197–251]

189

[171.5–212]

0.005

 INTEM CFT (s)

50.5

[39.5–61.8]

56

[39–63]

45

[39.5–60.5]

ns

 INTEM MCF (mm)

74

[69–77]

74

[65–77]

73

[69.5–78]

ns

 HEPTEM CT (s)

188.5

[170.5–208.3]

193

[173–209]

173

[159–206]

ns

 HEPTEM CFT (s)

41

[35.5–56.5]

40

[34–60]

42

[37–51]

ns

 HEPTEM MCF (mm)

73

[67.5–75.3]

73

[66–76]

71

[71–75]

ns

 ML, EXTEM (%)

3

[1.3–5.8]

3

[0–5]

5

[3.5–8]

0.001

 ML, INTEM (%)

3

[1–6]

2

[0–3]

6

[2.5–6]

0.001

  1. Unless values are designated as maximum values during the ICU stay, these parameters were determined on the day, when ROTEM analysis was performed, after admission to our ICUs
  2. CT clotting time, CFT clot formation time, MCF maximum clot firmness, ML maximum lysis